A new generic-industry joint venture linking New Jersey?based Amneal Pharmaceuticals and India?s Indoco Remedies will result in the marketing of at least 10 generic ophthalmic products in the United States.
Amneal?s role in the partnership will be to prepare and file abbreviated new drug applications for FDA approval and to exclusively market these products throughout the US pharmaceutical market. Indoco will be responsible for manufacturing the generics. Spokesmen for the 2 companies said that Indoco and Amneal have already begun to identify several more ophthalmic products to pursue, as well as other therapeutic categories and dosage forms.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs